Disc Medicine, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Disc Medicine, Inc. (IRON) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.23% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-02-26
- Disc Medicine, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2024-03-31 was 4.01%, a 3.89% increase year-over-year.
- Disc Medicine, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-03-31 was 3.86%, a 112.09% increase year-over-year.
- Disc Medicine, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2022-03-31 was 1.82%.
- Disc Medicine, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 4.23%, a 5.75% increase from fiscal 2024.
- Disc Medicine, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.00%, a 0.74% decline from fiscal 2023.
- Disc Medicine, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 4.03%, a 13.84% increase from fiscal 2022.
- Disc Medicine, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 3.54%, a 272.63% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2025-12-31 | 4.23% 10-K · filed 2026-02-26 | |||
| 2024-12-31 | 4.00% 10-K · filed 2026-02-26 | |||
| 2024-09-30 | 3.99% 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | 4.04% 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | 4.01% 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | 4.03% 10-K · filed 2026-02-26 | |||
| 2023-09-30 | 3.87% 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | 3.67% 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | 3.86% 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | 3.54% 10-K · filed 2024-03-21 | |||
| 2022-09-30 | 2.24% 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | 1.99% 10-Q · filed 2023-08-11 | |||
| 2022-03-31 | 1.82% 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | 0.95% 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |